slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 65,551-65,580
Pages 3,679
Rows per page 30
Component
65,551-65,580 of 110,355
26
Includes a footnote regarding excise taxes.AMMO | Investor Presentation Deck | 27 slides · AMMO, Inc.
Pitch deck Investor relations 1 hit
09
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
The chart uses a stacked bar approach to show captured vs. estimated visits, with trend lines indicating growth rates.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
24
The chart displays a time-course study of VAS (Visual Analog Scale) scores for 'feeling high' across three cohorts.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
25
VAS = Visual Analog Scale. Data shows a significant reduction in subjective 'high' feeling with ANEB-001 compared to placebo.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
26
The data shows a significant reduction in the proportion of subjects feeling high when treated with ANEB-001 compared to placebo.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
27
The chart shows a reduction in body sway for both 50mg and 100mg doses of ANEB-001 compared to placebo.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
28
The chart displays mean values with 95% confidence intervals. Statistical significance is indicated by asterisks.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
30
The slide uses a cascading process flow to show how multiple data streams feed into a central analysis and final model.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
34
Includes a smaller inset chart comparing current data to prior 50/100 mg dose data.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
35
Includes a smaller inset chart showing prior 50/100 mg data for comparison.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
36
Includes a primary chart and a smaller inset chart for comparison.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
37
Includes a primary chart and a smaller inset chart showing similar data for different dosage levels.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
38
The chart displays mean values with SEM error bars for various THC doses and ANEB-001 treatment groups.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
39
The slide displays PK data on both linear and log scales to demonstrate dose-related exposure and half-life characteristics.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
40
The slide compares six different treatment arms across two scales to demonstrate dose-related exposure.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
Uses two 2x2 matrices to position competitors relative to Apexigen.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The chart is a classic 'spider plot' used in oncology to track individual patient tumor burden over time.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
17
Includes Kaplan-Meier survival curve and comparative efficacy tables.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
19
Spider plot (swimmer plot variant) showing individual patient tumor response trajectories.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
22
The slide uses a biological process diagram to illustrate the mechanism of action.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations 1 hit
03
Comparison of Tmax metrics and safety profiles for single vs repeat dosing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses callout boxes connected to specific organs to detail symptom frequency and clinical manifestations.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Agitate (Make it worse)1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a scientific diagram of the signaling pathway and references to academic literature.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Includes a bifurcation diagram illustrating the relationship between SNAIL and ZEB mRNA levels in different cell phenotypes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
15
The slide includes two scatter plots with error bars and two summary tables of experimental data.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit